This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow [Online Tables]
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grootendorst, P. V.
Right arrow Articles by Levy, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grootendorst, P. V.
Right arrow Articles by Levy, A. R.
Related Collections
Right arrow Health Economics - see also Medicare
Right arrow Rationing
Right arrow Ischemic heart disease
Right arrow Drugs: cardiovascular system
Right arrow Other drug use
Right arrow Other medicare
CMAJ • October 16, 2001; 165 (8)
© 2001 Canadian Medical Association or its licensors

Research
Recherche

Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs

Paul V. Grootendorst*{dagger}, Lisa R. Dolovich{dagger}{ddagger}§, Bernie J. O'Brien*{dagger}, Anne M. Holbrook{dagger} and Adrian R. Levy**{dagger}{dagger}

From the *Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont.; {dagger}Centre for Evaluation of Medicines, St. Joseph's Hospital, Hamilton, Ont.; {ddagger}Faculty of Pharmacy, University of Toronto, Toronto, Ont.; §Department of Family Medicine, McMaster University, Hamilton, Ont.; ¶Division of Clinical Pharmacology, Department of Medicine, McMaster University, Hamilton, Ont.; **Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, BC; and {dagger}{dagger}Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC

Correspondence to: Dr. Paul Grootendorst, Centre for Evaluation of Medicines, St. Joseph's Hospital, 105 Main St. E, P1, Hamilton ON L8N 1G6; fax 905 528-7386; grootend{at}mcmaster.ca

Background: Reference-based pricing limits reimbursement for a group of drugs that are deemed therapeutically equivalent to the cost of the lowest-priced product within that group. We estimated the effect of reference-based pricing of nitrate drugs used for long-term prophylaxis on prescribing of and expenditures on nitrates and other anti-anginal drugs dispensed to senior citizens in British Columbia.

Methods: We assessed trends in the monthly volume of prescriptions of anti- anginal drugs and the associated drug ingredient cost paid by the province's publicly funded drug subsidy program, Pharmacare, and by the patients themselves for the period April 1994 to May 1999. Trends in monthly rates of nitrate expenditures per 100 000 senior citizens before the introduction of reference-based pricing were extrapolated to infer what expenditures would have been without the policy.

Results: During the 31/2 years after reference-based pricing was introduced, Pharmacare expenditures on nitrates prescribed to senior citizens declined by $14.9 million (95% confidence interval $10.7 to $19.1 million). Most of these savings were due to the lower prices that Pharmacare paid for sustained-release nitroglycerin tablets and the nitroglycerin patch, which were the 2 most frequently prescribed nitrates before the introduction of reference-based pricing; $1.2 million (8%) of the savings represented expenditures by senior citizens who purchased drugs that were only partially reimbursed. There were no compensatory increases in expenditures for other anti-anginal drugs. Use of sublingual nitroglycerin — a marker for deteriorating health in patients with angina — did not increase after the introduction of reference-based pricing. The nitroglycerin patch is now the most frequently prescribed nitrate, owing to the fact that Pharmacare resumed the provision of full subsidies for the drug after its manufacturers voluntarily reduced retail prices.

Interpretation: Evidence to date suggests that reference-based pricing of nitrates has achieved its primary goal of reducing drug expenditures. The effects of this policy on patient health, associated health care costs and administrative costs remain to be investigated.




This article has been cited by other articles:


Home page
 Psychiatr. Serv.Home page
P. S. Wang, A. R. Patrick, C. R. Dormuth, J. Avorn, M. Maclure, C. F. Canning, and S. Schneeweiss
The Impact of Cost Sharing on Antidepressant Use Among Older Adults in British Columbia
Psychiatr Serv, April 1, 2008; 59(4): 377 - 383.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. P. Goldman, G. F. Joyce, and Y. Zheng
Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health
JAMA, July 4, 2007; 298(1): 61 - 69.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Schneeweiss, A. R. Patrick, M. Maclure, C. R. Dormuth, and R. J. Glynn
Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction: A Population-Based Natural Experiment
Circulation, April 24, 2007; 115(16): 2128 - 2135.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
A. Briggs, M. Buxton, M. Drummond, R. Goeree, M. J. Sculpher, and A. R. Willan
Unfinished Symphony: A Tribute to the Life and Career of Bernie O'Brien (1959-2004)
Med Decis Making, October 1, 2004; 24(5): 538 - 544.
[Abstract] [PDF]

Home page
 Health Aff (Millwood)Home page
S. Morgan, K. Bassett, and B. Mintzes
Outcomes-Based Drug Coverage in British Columbia
Health Aff., May 1, 2004; 23(3): 269 - 276.
[Abstract] [Full Text] [PDF]

Home page
 Health Aff (Millwood)Home page
S. B. Soumerai
Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In Medicaid
Health Aff., January 1, 2004; 23(1): 135 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Health Aff (Millwood)Home page
S. G. Morgan, M. L. Barer, and J. D. Agnew
Whither Seniors' Pharmacare: Lessons From (And For) Canada
Health Aff., May 1, 2003; 22(3): 49 - 59.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
S. Schneeweiss, M. Maclure, C. Dormuth, and J. Avorn
Pharmaceutical cost containment with reference-based pricing: time for refinements
Can. Med. Assoc. J., November 26, 2002; 167(11): 1250 - 1251.
[Full Text] [PDF]